Anticancer Evaluation and Cellular-Stress Analyses of a Flavonol–Ruthenium(II) Complex Against Aggressive Breast Cancer Cells

Triple-negative breast cancer remains refractory to conventional chemotherapy, driving demand for selective metallopharmaceuticals that trigger immunogenic cell death and convert immune-desert “cold” tumors into immune-vulnerable “hot” tumors. Here, we delineate the in vitro efficacy and regulated cell death (RCD) landscape of compound 2 [RuCl(p-cymene)(4′-methoxyflavonol)], a half-sandwich Ru(II)–arene flavonol complex assembled from 3-hydroxy-4′-methoxyflavone and dichloro(p-cymene)ruthenium(II) dimer. Under 24 h CCK-8 assays, compound 2 potently inhibited aggressive breast cancer models—human MDA-MB-231 IC50 37.6 μM and murine 4T1 IC50 26.1 μM—while sparing non-malignant human mammary epithelial H184B5F5/M10 (IC50 72.6 μM, SI 1.9) and mouse embryonic fibroblasts (IC50 41.3 μM, SI 1.6), showing activity comparable to cisplatin (IC50 41.2 μM in MDA-MB-231) and superior to free ligand + Ru-dimer mixture (IC50 108.9 μM). Compound 2 exhibited favorable physiological stability and enhanced stability under mildly acidic, tumor-mimetic conditions, supporting a tumor-retentive prodrug behavior. CTS-RCDP multiparametric flow cytometry revealed a multimodal death network predominantly driven by pyroptosis (51.7% in MDA-MB-231, 40.1% in 4T1), accompanied by apoptosis, validated by caspase-1/-3 colorimetric assays (3.2-fold/2.4-fold increase, p < 0.01). This was coupled with pronounced elevation of mitochondrial mass and mtROS. Collectively, compound 2 emerges as a selective Ru-flavonol complex that drives pyroptosis-dominant cell death, a lytic, pro-inflammatory modality recognized to reprogram immunologically “cold” tumors into immune-vulnerable “hot” lesions.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-11-16
DOI
https://doi.org/10.3390/ijms272210279
Primary Topic
Metal complexes synthesis and properties
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Anticancer Evaluation and Cellular-Stress Analyses of a Flavonol–Ruthenium(II) Complex Against Aggressive Breast Cancer Cells

Te-Sheng Lien, Yu-Jui Su, Hsin‐Hou Chang, Ruo‐Chia Tseng et al.
2 links
International Journal of Molecular Sciences
Metal complexes synthesis and properties
article

Anticancer Evaluation and Cellular-Stress Analyses of a Flavonol–Ruthenium(II) Complex Against Aggressive Breast Cancer Cells

Te-Sheng Lien, Yu-Jui Su, Hsin‐Hou Chang, Ruo‐Chia Tseng, Ching‐Feng Cheng, Guan‐Ling Lin, Der‐Shan Sun, Tzenge‐Lien Shih, Hsin-Ying Wu, Yue-Cen Lai, Jen-Che Chang, Lian-Fu Yang
article en

Abstract

Triple-negative breast cancer remains refractory to conventional chemotherapy, driving demand for selective metallopharmaceuticals that trigger immunogenic cell death and convert immune-desert “cold” tumors into immune-vulnerable “hot” tumors. Here, we delineate the in vitro efficacy and regulated cell death (RCD) landscape of compound 2 [RuCl(p-cymene)(4′-methoxyflavonol)], a half-sandwich Ru(II)–arene flavonol complex assembled from 3-hydroxy-4′-methoxyflavone and dichloro(p-cymene)ruthenium(II) dimer. Under 24 h CCK-8 assays, compound 2 potently inhibited aggressive breast cancer models—human MDA-MB-231 IC50 37.6 μM and murine 4T1 IC50 26.1 μM—while sparing non-malignant human mammary epithelial H184B5F5/M10 (IC50 72.6 μM, SI 1.9) and mouse embryonic fibroblasts (IC50 41.3 μM, SI 1.6), showing activity comparable to cisplatin (IC50 41.2 μM in MDA-MB-231) and superior to free ligand + Ru-dimer mixture (IC50 108.9 μM). Compound 2 exhibited favorable physiological stability and enhanced stability under mildly acidic, tumor-mimetic conditions, supporting a tumor-retentive prodrug behavior. CTS-RCDP multiparametric flow cytometry revealed a multimodal death network predominantly driven by pyroptosis (51.7% in MDA-MB-231, 40.1% in 4T1), accompanied by apoptosis, validated by caspase-1/-3 colorimetric assays (3.2-fold/2.4-fold increase, p < 0.01). This was coupled with pronounced elevation of mitochondrial mass and mtROS. Collectively, compound 2 emerges as a selective Ru-flavonol complex that drives pyroptosis-dominant cell death, a lytic, pro-inflammatory modality recognized to reprogram immunologically “cold” tumors into immune-vulnerable “hot” lesions.

International Journal of Molecular SciencesVol. 27(22)
Tamkang University (TW), Tzu Chi University (TW), Institute of Biomedical Sciences, Academia Sinica (TW), Taipei Tzu Chi Hospital (TW), Taipei Medical University (TW), Academia Sinica (TW)
Good health and well-being
Metal complexes synthesis and properties
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon